Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
A-METHAPRED vs ACTICORT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Allergic reactions (severe or disabling),Dermatologic diseases (e.g., pemphigus, exfoliative dermatitis),Endocrine disorders (e.g., congenital adrenal hyperplasia, nonsuppurative thyroiditis),Gastrointestinal diseases (e.g., ulcerative colitis, Crohn's disease),Hematologic disorders (e.g., autoimmune hemolytic anemia, thrombocytopenia),Neoplastic diseases (e.g., leukemia, lymphoma),Nervous system disorders (e.g., multiple sclerosis exacerbations),Ophthalmic diseases (e.g., allergic conjunctivitis, optic neuritis),Renal diseases (e.g., nephrotic syndrome, lupus nephritis),Respiratory diseases (e.g., asthma exacerbations, sarcoidosis),Rheumatic disorders (e.g., rheumatoid arthritis, acute gouty arthritis),Organ transplantation (as part of immunosuppressive regimen)
Corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, contact dermatitis),Off-label: atopic dermatitis, lichen planus, discoid lupus erythematosus
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Primarily hepatic via CYP3A4 enzyme system, with minor contributions from other pathways.
Hepatic metabolism via CYP3A4; inactive metabolites excreted renally and biliary.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
74-90% bound primarily to corticosteroid-binding globulin (CBG) and albumin.
90% bound to albumin and corticosteroid-binding globulin
1.0-1.5 L/kg; indicates extensive tissue distribution.
1.2-1.5 L/kg; indicates extensive tissue distribution
Oral: ~80%; IM: ~100%.
Oral: 80-90%; IM: 100%
No specific dose adjustment required; use caution in severe renal impairment.
No dose adjustment necessary for acute use; for chronic therapy in severe renal impairment (e GFR <30 m L/min/1.73 m2), consider dose reduction by 50% to minimize mineralocorticoid effects.
No specific guidelines; caution in severe hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% due to reduced clearance.
0.5-1.7 mg/kg/day or 5-25 mg/m²/day in divided doses.
0.05-2 mg/kg/day orally divided every 6-8 hours, not to exceed 80 mg/day; adjust based on response and severity.
Lower initial doses recommended due to increased risk of osteoporosis, fluid retention, and immunosuppression.
Initiate at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor for adverse effects.
Corticosteroids, including methylprednisolone, may cause immunosuppression and increase susceptibility to infections. Live or live attenuated vaccines are contraindicated in patients receiving immunosuppressive doses. Administration of live vaccines may cause disseminated infection.
None
Increased risk of infections; monitor for signs of infection and avoid exposure to active infections.,Adrenal suppression may occur, especially with prolonged therapy; taper dosing gradually.,May cause fluid and electrolyte disturbances (e.g., sodium retention, potassium loss, hypertension).,Gastrointestinal perforation risk, especially in patients with inflammatory bowel disease or recent GI surgery.,Osteoporosis with long-term use.,Behavioral and mood disturbances (e.g., euphoria, depression, psychosis).,Cushing's syndrome with chronic use.,Exacerbation of diabetes mellitus, glaucoma, and cataracts.,High-dose therapy may cause acute myopathy, particularly in patients on neuromuscular blocking agents.
HPA axis suppression with prolonged use or large surface area,Local irritation and skin atrophy,Systemic absorption with occlusive dressings,Potential for rebound effects after discontinuation
Systemic fungal infections,Hypersensitivity to methylprednisolone or any component of the formulation,Administration of live or live attenuated vaccines in immunosuppressive doses,Idiopathic thrombocytopenic purpura (IM route only)
Known hypersensitivity to components,Untreated bacterial/fungal infections,Viral skin infections (e.g., herpes simplex, varicella),Perioral dermatitis, rosacea
Avoid grapefruit and grapefruit juice as they may increase methylprednisolone levels. Limit sodium intake to reduce fluid retention. Avoid alcohol due to increased risk of gastrointestinal bleeding. Maintain adequate calcium and vitamin D intake to prevent bone loss.
No clinically significant food interactions. Alcohol may increase systemic absorption if tympanic membrane is perforated, but generally avoid alcohol-based ear drops if perforation suspected.
First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal suppression, intrauterine growth restriction, and preterm birth. Risk is dose- and duration-dependent.
First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnios with chronic use. Avoid use unless maternal benefit outweighs risks.
Prednisolone (active metabolite) is excreted into breast milk, with an M/P ratio approximately 5:1 to 20:1. The relative infant dose is estimated at <10% of maternal weight-adjusted dose. Monitor infant for adrenal suppression and growth. Nursing should be timed 3-4 hours after maternal dose.
Prednisone enters breast milk at low levels (M/P ratio ~0.1-0.3). At maternal doses ≤20 mg/day, the infant dose is <10% of maternal weight-adjusted dose. Consider risk of adrenal suppression in infant with high-dose, long-term therapy. AAP rates as compatible with breastfeeding.
Dose adjustment may be necessary due to increased clearance of prednisolone in pregnancy. Dose should be individualized, often with increased doses during pregnancy and reduced postpartum. No standard fixed adjustment; monitor clinical response.
No empirical dose adjustment required; however, pharmacokinetic changes (increased Vd, hepatic metabolism) may reduce efficacy. Doses may need to be increased by 20-30% in third trimester if disease activity increases. Taper to lowest effective dose.
A-Methapred is a brand of methylprednisolone sodium succinate. For acute spinal cord injury, administer within 8 hours with a bolus of 30 mg/kg over 15 minutes, followed by a 45-minute pause, then 5.4 mg/kg/hour for 23 hours. Monitor for hyperglycemia, especially in diabetic patients; consider insulin sliding scale. Taper dose if used for >5 days to avoid adrenal insufficiency. Avoid abrupt discontinuation.
ACTICORT (hydrocortisone/neomycin/polymyxin B) is a topical combination used for inflammatory ear conditions. Avoid prolonged use (>10 days) to prevent sensitization and overgrowth of non-susceptible organisms. Tympanic membrane perforation is a contraindication due to ototoxicity risk. Use the otic solution not the ophthalmic suspension for ear infections.
Do not stop taking this medication suddenly without consulting your doctor; dosage must be tapered gradually.,Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately.,Avoid live vaccines while on this medication.,Take with food or milk to reduce stomach upset.,Carry a medical alert card stating you are taking corticosteroids.,Do not miss doses; take exactly as prescribed.
Instill drops while lying down with affected ear upward, then remain in position for 5 minutes.,Do not touch dropper to ear or any surface to avoid contamination.,Complete full course even if symptoms improve; do not use longer than prescribed.,Report worsening redness, swelling, or hearing loss immediately.,Avoid getting water in ear during treatment; use a cotton ball soaked in petroleum jelly to protect ear when showering.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about A-METHAPRED vs ACTICORT, answered by our medical review team.
A-METHAPRED is a Corticosteroid that works by Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.. ACTICORT is a Corticosteroid that works by Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between A-METHAPRED and ACTICORT depend on the specific clinical indication. These are both Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of A-METHAPRED is: Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.. The standard adult dose of ACTICORT is: 5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between A-METHAPRED and ACTICORT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. A-METHAPRED is classified as Category C. First trimester: Corticosteroids are associated with a small increased risk of oral clefts (odds ratio ~1.5). Second and third trimesters: Chronic use may lead to fetal adrenal sup. ACTICORT is classified as Category C. First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.